Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Germany to introduce fixed health insurance payments as part of healthcare reforms
Today
Germany's health ministry is planning to introduce fixed health insurance fees as part of its reforms to bring stability to the healthcare system. The ministries of health, finance, justice, work and consumer affairs will meet tomorrow to discuss the strategy. The new coalition government, formed by the Christian Democrats, the Christian Social Union and the Free Democrats, aims to stabilise health insurance income. However, it is unclear whether this reform will generate more income for the ...
 
Emerging markets to make up 48% of pharma growth, IMS Health says
Today
IMS Health is predicting that emerging markets will expand by $90 billion during 2009-13, contributing 48% of annual pharmaceutical market growth in 2013, a jump from 37% in 2009. This comes at time when many multinational pharma firms are looking to these markets –with their rising GDPs, ...
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the CYP2C1P liver enzyme leading to reduced formation of ...
 
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the CYP2C1P liver enzyme leading to reduced formation of ...
Pfizer faces disappointment with anticancers after more Phase III failures
12 March 2010
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - ending development for the drug in the disease - and figitumumab (CP-751,871), one of the most advanced (IGF-1) ...
 
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the CYP2C1P liver enzyme leading to reduced formation of ...
Access to medicines concerns in EU-India trade agreement
12 March 2010
The international humanitarian body Médecins Sans Frontières (MSF) has written to the Indian prime minister, Dr Manmohan Singh , expressing concern that the EU-India free trade agreement, which will have its sixth negotiating round in Brussels in April, will contain intellectual property (IP) ...
 
Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
Today
Merck / Portola Pharmaceuticals ' investigational Factor Xa inhibiting anticoagulant betrixaban was associated with significantly less clinically relevant bleeding than warfarin when given at 40mg/day to patients with atrial fibrillation, show new results from a dose-finding study presented on ...
ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
15 March 2010
Hypolipaemic fenofibrates such as Abbott s' TriCor, its next-generation Trilipix and generics, do not improve cardiovascular outcomes in patients with type 2 diabetes when used in combination with simvastatin (Merck & Co's lipid-lowering Zocor). The much-awaited ACCORD LIPID data were presented ...
 
Ranbaxy settles with Takeda on Actos suit
15 March 2010
Ranbaxy Laboratories has settled outstanding patent litigation with Takeda Pharmaceutical Company , allowing it to launch a generic version of Takeda's antidiabetic, Actos (pioglitazone hydrochloride), in the US. Under the deal, Ranbaxy can launch its generic equivalent of Actos on August 17th ...
Access to medicines concerns in EU-India trade agreement
12 March 2010
The international humanitarian body Médecins Sans Frontières (MSF) has written to the Indian prime minister, Dr Manmohan Singh , expressing concern that the EU-India free trade agreement, which will have its sixth negotiating round in Brussels in April, will contain intellectual property (IP) ...
 
EXPERT VIEW
The difference between legal and scientific substitutability
11 September 2009
Faraz Kermani
The tussle between Germany’s research-based pharmaceutical industry and health insurers over ...

Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010

Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of ...

 Market Insight - Fear gives way to prudence a...
 Market Insight - Power of observation propels...

How to run clinical trials in the Middle East - Egypt
04 March 2010

The population of Egypt is 83.1 million and the GDP per capita is $5,400. The country's healthcare ...

How to run clinical trials in the Middle East - why the GCC?
04 March 2010

A grouping of Middle Eastern countries came together under the auspices of the Gulf Co-operation ...

Private investment round-up: February 2010
15 March 2010
Just as it appeared that the private investment market was beginning to rebound after last year's ...

European Medicines Agency and logos: snakes, DNA and the pestle and mortar
22 December 2009
Elizabeth Sukkar
Logos are said to be an important part of an organisation's branding. Really good logos contribute ...

Spanish generics industry fights for its future
22 July 2009
Francesca Bruce
Spain's generic medicines industry could be in trouble. In 2008, for the first time since generics ...

Focus on Regulatory Affairs
10 September 2008
Advanced thinking - New regulation set to come into effect across the EU this December aims to ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm